Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
In vitro experimental study of nanoparticle synthesis and characterization with antimicrobial testing against a single bacterial strain; no clinical data, comparative quantification, or validation in relevant systems.
Cross-sectional survey with very small biological subsample (n=64) and surrogate endpoints; establishes prevalence estimates but lacks comparator group design and cannot determine causation or temporal relationships.
Cardiovascular & Haematological Disorders - Drug Targets
This is a narrative review synthesizing clinical trial evidence and guideline recommendations on two drug classes for metabolic syndrome in type 2 diabetes, without presenting original data or a systematic meta-analytic synthesis.
A single-centre, quasi-experimental comparison showing superiority of vilazodone over escitalopram on depression severity, but limited by single-blind design, lack of active comparator control, and modest sample size without prespecified primary endpoints.
A literature review summarizing clinical development, technical principles, and experimental results of cell therapy approaches for diabetes, offering a reference for research and clinical translation rather than reporting primary evidence.
Journal of Pharmaceutical Research and Integrated Medical Sciences
A narrative review of AI applications in nanomedicine oncology that raises conceptual possibilities and identifies research directions rather than reporting empirical results or clinical outcomes.
Cross-sectional prevalence study from a single region without effect sizes, confidence intervals, or comparative analysis; descriptive findings support hypothesis generation rather than clinical decision-making.
Single-centre retrospective study with modest sample size identifies ALBI score as prognostic for survival after TARE, but lacks prospective design, external validation, and mechanistic insight into clinical benefit.